Real‐world multiple myeloma front‐line treatment and outcomes by transplant in the United States

Abstract

AbstractStem cell transplantation (SCT) has been an integral treatment modality for multiple myeloma (MM) for decades. However, as standard‐of‐care therapies have improved, the benefit of SCT has been repeatedly called into question. This retrospective study evaluated the association between SCT in the first line of therapy (LOT) and outcomes for patients with newly diagnosed multiple myeloma (NDMM) in the United States. We included patients from a de‐identified electronic health record‐derived database who initiated front‐line MM therapy between January 1, 2016, and January 31, 2022. Overall, 18.8% (1127 of 5996 patients) received SCT in the first LOT. Multivariable‐adjusted Cox proportional hazards models, in which SCT was modeled as time varying, revealed longer real‐world progression‐free survival (rwPFS; hazard ratio [HR] 0.49; 95% confidence interval [CI] 0.43–0.57) and real‐world overall survival (rwOS; HR 0.47; 95% CI 0.39–0.56) for patients who received SCT in the first LOT. The degree of rwPFS and rwOS benefit imparted by SCT was consistent across all subgroups examined, including patients aged ≥75 years, women, non‐Hispanic Black/African American patients, those with renal impairment, and those with high‐risk cytogenetics. Findings from this analysis of real‐world patients with NDMM suggest that SCT remains an important standard of care in the era of novel therapies.